Bill
Bill > HB718
MS HB718
Opioid use disorder; require substance use disorder facilities to provide pregnant women with onsite access to certain treatments.
summary
Introduced
01/15/2025
01/15/2025
In Committee
01/15/2025
01/15/2025
Crossed Over
Passed
Dead
02/04/2025
02/04/2025
Introduced Session
2025 Regular Session
Bill Summary
An Act To Require Each Substance Use Disorder Facility That Provides Treatment For Opioid Use Disorder To Pregnant Women To Provide Onsite Access To At Least One Form Of Fda-approved Opioid Agonist Treatment; To Define The Term "substance Use Disorder Facility" As A Facility Or Program Operated Or Certified By The State Department Of Mental Health That Provides Treatment To Persons With Substance Use Disorders; To Define The Term "onsite Access" As Delivery Of The Treatment To The Patient At The Location Of The Substance Use Disorder Facility; To Require, From And After July 1, 2026, Each Substance Use Disorder Facility Subject To The Requirements Of This Act That Is Certified By The Department To Submit To The Department On Its Initial Certification Application Or Its Certification Renewal Application An Attestation As To Whether It Is Complying With The Requirements Of This Act; To Direct The Department To Monitor Compliance By Substance Use Disorder Facilities With The Requirements Of This Act To Ensure Continued Access To Opioid Use Disorder Treatment For Pregnant Women, And To Make Certain Reports Annually To The Public Health Committees Of The House And Senate; And For Related Purposes.
AI Summary
This bill requires substance use disorder facilities in Mississippi that provide treatment to pregnant women with opioid use disorder to offer onsite access to at least one FDA-approved opioid agonist treatment (medication that helps manage opioid addiction) starting July 1, 2025. The bill defines key terms such as "onsite access" as delivering treatment at the facility location, though facilities are not required to keep medication in stock, and "substance use disorder facility" as a state-certified program treating people with substance use disorders. From January 1, 2026, these facilities must submit an attestation with their certification applications confirming their compliance or detailing their progress toward meeting the requirements. The State Department of Mental Health will monitor compliance and annually report to legislative committees on the number of pregnant women receiving opioid use disorder medications and the number of facilities providing such treatment. A facility would not be considered in violation if insurance preapproval for treatment is denied. The overall aim is to improve treatment access for pregnant women struggling with opioid addiction.
Committee Categories
Health and Social Services
Sponsors (1)
Last Action
Died In Committee (on 02/04/2025)
Official Document
bill text
bill summary
Loading...
bill summary
Loading...
bill summary
| Document Type | Source Location |
|---|---|
| State Bill Page | https://billstatus.ls.state.ms.us/2025/pdf/history/HB/HB0718.xml |
| BillText | https://billstatus.ls.state.ms.us/documents/2025/html/HB/0700-0799/HB0718IN.htm |
Loading...